Eli Lilly's full-year guidance comes in stark contrast to the outlook of Novo Nordisk, which warned it sees sales and profit ...

Eli Lilly reports fourth-quarter earnings and revenue that handily top expectations and issues solid guidance.

The split in outlook underscores Lilly's strong position in the obesity market, underpinned by more effective drugs and its ...

Eli Lilly beat profit estimates and issued strong guidance as demand for its weight-loss drugs surged, even as pricing ...

Lilly has also signaled that seven more Phase 3 trials for retatrutide are expected to conclude in 2026, making it a pivotal ...

Eli Lilly & Co. provided an upbeat sales forecast for the year Wednesday as strong demand for its weight loss drug cemented its position at the top of the obesity market.

By Leah Douglas WASHINGTON, Jan 30 (Reuters) - Eli Lilly announced on Friday that it will build a pharmaceutical ...

Eli Lilly (LLY) stock in focus as EU drug regular declines to endorse heart failure as a new indication for the company's GLP ...

Both companies may succeed in this industry.

A long-acting shot Pfizer got through a buyout of Metsera appeared “slightly inferior” to Lilly’s market-leading Zepbound in ...